Analyzing the Future of End Stage Renal Disease (ESRD) Drug Market Dynamics 2025-2034: Growth Rate, Trends, and Major Opportunities
Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!
What Growth Opportunities are Expected to Drive the End Stage Renal Disease ESRD Drug Market’s CAGR Through 2034?
The market size for end-stage renal disease (ESRD) drug has experienced swift growth in recent years, expanding from $131.41 billion in 2024 to an anticipated $149.88 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 14.1%. The unprecedented growth recorded in the historical period can be traced back to rising cases of end stage renal disease, a burgeoning elderly population, enhanced accessibility to healthcare services, governmental strategies and guidelines, and the increasing uptake of renal replacement therapies.
The market for drugs treating end stage renal disease (ESRD) is predicted to witness rapid expansion in the upcoming years, with the projected size expected to reach $268.44 billion by 2029, reflecting a compound annual growth rate (CAGR) of 15.7%. The anticipated growth during the forecast period can be ascribed to the development of new therapies and innovative drugs, increased spending on healthcare, the escalating worldwide incidence of chronic kidney diseases, individualized medical treatment strategies, regulatory assistance, and faster approval processes. Key trends during the forecast period encompass the rising prevalence of end stage renal disease, improvements in treatment methods, increasing focus on precision medicine, the creation of hybrid therapies, and the incorporation of technology in healthcare.
What Major Innovations Are Driving the Accelerated Growth of the end stage renal disease esrd drug Market?
The surge in obesity and diabetes is anticipated to fuel the progression of the end-stage renal disease (ESRD) drug market. Obesity is characterized as abnormal or excess fat accumulation that constitutes a health risk, while diabetes is a long-term condition that occurs when the pancreas fails to produce sufficient insulin or the body is unable to use the insulin produced effectively. In renal disease patients, maintaining fluid and electrolyte levels, blood pressure, and the elimination of waste products through dialysis can enhance overall health and potential weight loss, thus improving blood sugar management. For example, World Obesity, a US-based member organization dedicated to obesity study and management, projected in March 2022 that the number of obese individuals could escalate to 892 million by 2025 and then to 1,025 million by 2030. Moreover, the National Health Service, a UK-based publicly funded healthcare system, predicted in February 2023 that the number of diabetics in the UK might hit 5.5 million by 2030, affecting nearly 9% of the populace. Hence, the increasing prevalence of obesity and diabetes is set to catalyze the end-stage renal disease (ESRD) drug market.
Get Your Free Sample of the Global End Stage Renal Disease ESRD Drug Market Report Now!
https://www.thebusinessresearchcompany.com/sample.aspx?id=9437&type=smp
What Are the Top Market Players Propelling the Growth of the End Stage Renal Disease ESRD Drug Industry?
Major companies operating in the end stage renal disease (ESRD) drug market include:
• Pfizer Inc._x000D_
• AstraZeneca plc_x000D_
• Sanofi SA_x000D_
• Astellas Pharma Inc._x000D_
• Novartis AG_x000D_
What Are the Key Trends to Watch in the End Stage Renal Disease ESRD Drug Market Over the Coming Years?
A significant trend observed in the end-stage renal disease (ESRD) drug market is the prioritization of product innovations. Leading entities in the ESRD drug market are prioritizing innovative solutions to maintain their foothold in the market. For instance, April 2022 saw GlaxoSmithKline PLC, a renowned pharmaceutical and biotechnology company from the UK, inform the public that the US Food and Drug Administration (FDA) had approved the New Drug Application (NDA) for daprodustat. This drug is an oral hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI) and could potentially treat patients with chronic kidney disease anemia (CKD). The foundation of this unique product lies in the Nobel-prize winning research that explores how cells adapt to changes in oxygen availability.
Get Instant Access to the Global End Stage Renal Disease ESRD Drug Market Report with Swift Delivery!
How Are Market Segments in the End Stage Renal Disease ESRD Drug Industry Positioned for Long-Term Growth?
The end stage renal disease (ESRD) drug market covered in this report is segmented –
1) By Product Type: Calcimimetics, Vitamin D, Sterols, Potassium Binders, Calcium-Based Phosphate Binders, Other Products
2) By Indication: End Stage Renal Disease (ESRD) Induced Hyperparathyroidism, End Stage Renal Disease (ESRD) Induced Hyperphosphatemia, End Stage Renal Disease (ESRD) Induced Hyperkaliemia
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy
4) By End User: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Calcimimetics: Cinacalcet, Etelcalcetide
2) By Vitamin D: Calcitriol, Doxercalciferol, Paricalcitol
3) By Sterols: Ergocalciferol, Cholecalciferol
4) By Potassium Binders: Sodium Polystyrene Sulfonate, Patiromer, Sodium Zirconium Cyclosilicate
5) By Calcium-Based Phosphate Binders: Calcium Acetate, Calcium Carbonate
6) By Other Products: Iron Supplements, Erythropoiesis-Stimulating Agents
What Regions Are Dominating the End Stage Renal Disease ESRD Drug Market Growth?
North America was the largest region in the end stage renal disease (ESRD) drug market in 2024. The regions covered in the end stage renal disease (ESRD) drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
What Are the Key Characteristics That Define the End Stage Renal Disease ESRD Drug Market?
End stage renal disease (ESRD) drug is a drug used to treat a medical illness in which a person’s kidneys stop working permanently, requiring a kidney transplant or a regular regimen of long-term dialysis to protect life. It is crucial in treating and preventing secondary problems in individuals with chronic renal disease (CKD).
Browse Through More Similar Reports By The Business Research Company:
Musculoskeletal Disorders Drugs Global Market Report 2022
Central Nervous System Drugs Global Market Report 2022
https://www.thebusinessresearchcompany.com/report/central-nervous-system-drug-global-market-report
Cardiovascular Drugs Global Market Report 2022
https://www.thebusinessresearchcompany.com/report/cardiovascular-drugs-global-market-report
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Contact us at:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 3156230293
Asia +44 2071930708
Europe +44 2071930708
Email us at [email protected]
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
Found this article helpful? Share it on:
